对HER2阳性乳腺癌的分子表征和分类为量身定制的治疗策略提供信息
Yu-Wei Li1,2, Lei-Jie Dai1,2, Xiang-Rong Wu1,2
1Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Cancer research
|August 26, 2024
概括
HER2阳性乳腺癌不是一种单一的疾病. 研究人员确定了四种具有独特分子特征的亚型,使得个性化治疗策略能够在这种侵略性癌症中获得更好的结果.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 翻译研究是翻译研究.
背景情况:
- HER2阳性乳腺癌是一种攻击性的亚型,占所有乳腺癌的15-20%.
- 现有证据表明,在HER2阳性乳腺癌中存在显著的异质性,影响治疗反应.
- 了解这种异质性对于开发精确的治疗策略至关重要.
研究的目的:
- 为了研究HER2阳性乳腺癌的分子异质性.
- 根据转录组概况识别来识别不同的分子亚型.
- 为每个已识别的亚型探索量身定制的治疗策略.
主要方法:
- 一个HER2阳性乳腺癌队列的多基因分析.
- 基于转录组的亚型分析.
- 在患者衍生器官和瘤碎片模型中的验证.
主要成果:
- 鉴定出了四种不同的基于转录组的亚型:HER2-CLA,HER2-IM,HER2-LUM和HER2-BM.
- 每个亚型都表现出独特的分子特征和潜在的治疗脆弱性.
- HER2-CLA对抗HER2疗法反应良好,HER2-IM对免疫疗法反应良好,HER2-LUM对内分泌疗法反应良好,HER2-BM可能受益于氨酸激酶抑制剂.
结论:
- HER2阳性乳腺癌是分子异质的,需要特定亚型的治疗方法.
- 已识别的亚型为 HER2 阳性乳腺癌的个性化医疗提供了框架.
- 这项研究为更为定制和有效的治疗策略铺平了道路.
更多相关视频
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
87
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.6K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer
48.2K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
48.2K
